Gennex Laboratories Limited announced the appointment of Ms. Khushbu Kachhawa as Additional Non-Executive Independent Women Director, effective February 14, 2026. The appointment was approved by the Board of Directors based on the recommendation of the Nomination & Remuneration Committee and is subject to shareholder approval.

Director Appointment Details

Ms. Khushbu Kachhawa brings professional expertise to the board with her educational background and experience in corporate affairs. The appointment strengthens the company's board composition and governance structure.

Professional Background

Ms. Kachhawa has approximately 5 years of experience in handling business affairs and corporate secretarial matters. She is not related to any Directors or Key Managerial Personnel of the company and fulfills the criteria required under the provisions of the Companies Act, 2013 and the Listing Regulations.

Regulatory Compliance

The appointment has been made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ms. Kachhawa is not debarred from holding the office of director by virtue of any SEBI order or any other authority. The company has filed the necessary disclosures including Form B under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Corporate Governance Enhancement

This appointment is part of Gennex Laboratories' ongoing commitment to strengthening its corporate governance framework. The addition of an independent women director aligns with regulatory requirements and enhances board diversity. The pharmaceutical company, which specializes in bulk drugs manufacturing including Guaifenesin and Methocarbamol, continues to focus on maintaining robust governance standards alongside its operational growth.

Gennex Laboratories Limited , a prominent player in the bulk drugs and biotech products sector, has announced its financial results for the first quarter, showcasing significant growth in both revenue and profitability.

Strong Revenue Growth

The company reported a substantial increase in its standalone revenue, which rose to Rs 2,564.00 lacs, marking a 20.2% growth compared to Rs 2,133.40 lacs in the same quarter of the previous year. This impressive top-line performance underscores the company's strong market position and effective growth strategies.

Profit Performance

Gennex Laboratories demonstrated resilience in its bottom line, with standalone net profit reaching Rs 414.95 lacs, compared to Rs 416.60 lacs in the corresponding quarter last year. While this represents a marginal decrease of 0.4%, it's worth noting that the company maintained a robust profit level despite potential challenges in the operating environment.

Consolidated Results

On a consolidated basis, which includes the performance of its subsidiary, Deccan Remedies Ltd, Gennex Laboratories reported even stronger results:

• Consolidated revenue stood at Rs 3,417.75 lacs, up 20.7% from Rs 2,832.18 lacs in the previous year's quarter.
• Consolidated net profit increased to Rs 501.64 lacs, showing a 7.7% growth compared to Rs 465.84 lacs in the same period last year.

Operational Highlights

The company's operational efficiency is evident from its financial statements:

Earnings Per Share and Capital Structure

The company reported a slight decrease in its standalone basic earnings per share (EPS) to Rs 0.18 from Rs 0.18 year-over-year. However, the consolidated basic EPS improved to Rs 0.22 from Rs 0.21 year-over-year.

Gennex Laboratories' paid-up equity share capital increased to Rs 2,314.48 lacs, compared to Rs 2,274.48 lacs in the previous year, indicating potential capital raising activities or stock-based compensation issuances.

Management Commentary

While specific management comments were not provided in the LODR data, the strong financial performance suggests that Gennex Laboratories' focus on its core business of bulk drugs, biotech products, and intermediates continues to yield positive results.

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting. The company's statutory auditors have carried out a limited review of these results in accordance with the regulatory requirements.

Investors and stakeholders can access the detailed quarterly unaudited financial results on the company's website ( www.gennexlab.com ) and the BSE website ( www.bseindia.com ).

As Gennex Laboratories continues to demonstrate strong growth and maintain profitability, it remains well-positioned in the pharmaceutical and biotech sectors, with its Q1 results reflecting the company's resilience and operational strength in a dynamic market environment.